American Association for Cancer Research

Poster Session B

POSTER SESSION B

Monday, Jan. 20 • 1-3 p.m.

In board assignment order

  • (B01) Green tea and quercetin sensitized castration-resistant prostate cancer cells to docetaxel treatment, Piwen Wang.
  • (B02, PR08) A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer, Akash Patnaik.
  • (B03) Galeterone overcomes second-generation antiandrogen resistance in vitro, Nader Al Nakouzi.
  • (B04) Effect of a selective CYP17-lysase inhibitor, VT464, on androgen receptor signaling in prostate cancer cells and on tumor growth of a patient-derived castrate-resistant prostate cancer xenograft, Sankar N. Maity.
  • (B05) Farnesoid-X-receptor: A novel pharmacological target for the treatment of prostate cancer, Louis Gauthier-Landry.
  • (B07) Sintokamide A inhibits castration resistant prostate cancer by targeting the amino-terminus of the androgen receptor, Carmen Adriana Banuelos.
  • (B08) Virotherapy of canine tumor xenografts with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody, Sandeep S. Patil.
  • (B09) JAK2 inhibition as a novel treatment for castration resistant prostate cancer (CRPC), Jacob Kach.
  • (B10) Inhibition of prostate cancer bone metastases by a novel Tiam1 inhibitor, Emmanuelle J. Meuillet.
  • (B11) Targeting integrin alpha6 stimulates curative-type bone metastasis lesions in a xenograft model, Terry H. Landowski.
  • (B12) Potential impact of ERG-typing on the biology and biomarker utility in the context of ethnic differences of prostate cancer, Albert Dobi.
  • (B13) TMPRSS2-ERG fusions regulate intratumoral androgen production in prostate cancer cells, Sreenivasa R. Chinni.
  • (B14) Co-targeting of the androgen receptor and Hsp90 prevents nuclear localization of the androgen receptor and induction of the heat shock response in prostate cancer cells, Margaret M. Centenera.
  • (B16) Chromosome 8 alterations and PTEN loss in Gleason grade 3 cores predict the presence of unsampled grade 4 tumor: Implications for active surveillance, Bruce J. Trock.
  • (B17) NuSAP is regulated by RB1 and modulates prostate cancer progression, Catherine A. Gordon.
  • (B18) Targeting FOXM1 reduces the viability of Enzalutamide resistant prostate cancer cells, Kirsi Ketola.
  • (B19) In vivo role of miR-32 in prostate cancer, Leena Latonen.
  • (B20, PR09) Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells, Tanya Stoyanova.
  • (B21) ETS and AP-1 transcription factors integrate RAS/ERK and PI3K/AKT signaling to regulate prostate cell migration, Peter C. Hollenhorst.
  • (B22) Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer, Steven Kregel.
  • (B23) CD133 expression marks rapidly proliferating cells in human prostate cancer, Edwin E. Reyes.
  • (B24) Delineation of the biological link between the ERG splice variant, ERG8, and its prognostic features, Anshu Rastogi.
  • (B25) Use of short tandem repeat profiling and DNA based mycoplasma analysis for authentication of human and mouse cell Llnes, Michael L. Baird.
  • (B26) Single-CTC whole genome sequencing in prostate cancer, Yi-Tsung Lu.
  • (B27) Quantitative in-depth proteomic profiling of FFPE prostate cancer tissues, Diego Iglesias-Gato.
  • (B28) Redox Factor-1 regulates drug resistance in prostate cancer cells via survival protein induction, Travis J. Jerde.
  • (B29) Targeting enzalutamide resistance with combination AKT and AR pathway inhibition, Paul Toren.
  • (B30) Transcriptome-wide analysis of prostate biomarkers in matching tumor and non-neoplastic samples from biopsy and radical prostatectomy, Jeffry P. Simko.
  • (B31) Global alternative splicing detection pipeline (I-GRASP) for analysis of splicing signatures in prostate cancer, Anna Lapuk.
  • (B32) The tyrphostin, NT157, potently suppresses insulin receptor substrates and induces apoptosis in prostate cancer cells, Michael E. Cox.
  • (B33) Interleukin-15 inhibits prostate cancer cell migration, Magaly Martinez-Ferrer.
  • (B34) Epigenetic regulation of MST1/STK4 expression by a cooperative MYC and EZH2 signaling in prostate cancer cells, Bekir Cinar.
  • (B35, PR10) CpG-STAT3 siRNA for therapy of castration-resistant prostate cancers, Marcin Kortylewski.
  • (B36) Altered periprostatic adipose tissue composition may predict prostate cancer aggressiveness, Palamadai N. Venkatasubramanian.
  • (B38) PARP inhibitor nanotherapy and radiosensitization for prostate cancer, Srinivas Sridhar.
  • (B39) Smart brachytherapy spacers eluting nanoencapsulated radiosensitizers for chemo-radiation therapy of prostate cancer, Srinivas Sridhar.
  • (B40) Helsinki Urological Biobank (HUB): A new-generation integrated biobank for facilitating precision medicine and translational research in urological cancers, Tuomas Mirtti.
  • (B41) Cross-species analysis of genome-wide regulatory networks identifies a synergistic dependency between FOXM1 and CENPF that drives prostate cancer malignancy, Alvaro Aytes.
  • (B42) Identification of SNPs associated with prostate cancer risk that are linked in trans to RNA expression changes in tumor-adjacent stroma, Xin Chen.
  • (B43) Androgen receptor independent acquired mechanisms of resistance to enzalutamide in castration-resistant prostate cancer, Steven Kregel.
  • (B44, PR11) Immune evasion strategies of neuroendocrine-like enzalutamide resistant prostate cancer, Jennifer L. Bishop.
  • (B45) Targeted sequencing of circulating tumor cells (CTCs) in hormone-sensitive prostate cancer, Brian Hu.
  • (B46) An innate developmental lineage plasticity of prostate cancer cells revealed by a new cell culture paradigm, Ralph Buttyan.
  • (B47) Chronic use of NSAIDs and/or statins does not impact longitudinal PSA or PSA velocity in men at high risk for prostate cancer, Steven P. Stratton.
  • (B48) Serum fucosylated haptoglobin is a novel type of prognostic biomarker predicting prostate cancer with Gleason score 7 or more, Kazutoshi Fujita.
  • (B50) How diet and exercise can re-tune metabolism to prevent aggressive prostate cancer, Richard Mithen.
  • (B51) Circulating vitamin D and inflammation in lethal prostate cancer, Julia O. Udesky.
  • (B52) A laboratory metabolomics assay, Prostarix, to stratify men at risk for prostate cancer prior to prostate biopsy, Jonathan McDunn.
  • (B53) A molecular portrait of Gleason 7 prostate cancer, Michael Fraser.
  • (B54) Regulation of the cell cycle on progression in PC-3 human prostate cells treatment by medicinal plant, Gronwell seed, Harukuni Tokuda.
  • (B55) The effects of PSMA on prostate carcinogenesis is modifiable by dietary folate and glutamate carboxypeptidase II inhibitors, Dean J. Bacich.
  • (B56) ERG suppresses ANXA2 expression and function in prostate cancer and ERG and ANXA2 expression patterns correlates with tumor differentiation, Nicholas B. Griner.
  • (B57, PR12) Mechanisms of clonal progression from Gleason 3 to Gleason 4 prostate cancer, Adam G. Sowalsky.
  • (B58) Androgen resistance in prostate cancer is associated with an enrichment of stem-like cells, Lisa Y. Wu.
  • (B59) Integrative sequencing reveals alterations in untreated and castration resistant prostate cancer, Matti Annala.
  • (B60) Low systemic testosterone levels induce androgen maintenance and changes in androgen receptor signaling in benign rodent prostate tissue, Jeremy O. Jones.
  • (B61) Coordinate loss of CHD1 and MAP3K7 promotes aggressive prostate cancer, Leah Rider.
  • (B62) Castrate resistant growth in the bone niche of novel patient-derived xenograft models of bone metastatic prostate cancer, Christina A.M. Jamieson.
  • (B63) The vitamin K cycle modulates androgen receptor activity differently in benign and cancerous prostate cells, Ben Yi Tew.
  • (B64) Intensive androgen deprivation therapy compensatorily activates PLZF-repressed oncogenic circuitry that reprograms the residual prostate cancer, Chen-Lin Hsieh.
  • (B65) Castration resistance to metastasis: Crucial role of neogenin in prostate tumorigenesis, Goutam Chakraborty.
  • (B66) In vivo quantitative phosphoproteomic profiling identifies PAK2 as a regulator of castration resistant prostate cancer growth, Amilcar Flores-Morales.
  • (B67) Ron receptor signaling promotes obesity-induced prostate tumor growth and metastatic dissemination, Nicholas E. Brown.
  • (B68) SRC family kinase FYN promotes MET tyrosine kinase activation, epithelial to mesenchymal transition and metastasis in human prostate cancer, Murali Gururajan.
  • (B69) HGFL promotes prostate tumorigenesis in a murine model of prostate cancer, Juozas Vasiliauskas.
  • (B70) Myc and Pten govern a prostate epithelial differentiation program involving ING4; Disruption of which is necessary for human prostate cancer development, Cindy K. Miranti.